A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272)

🧪 Interventions in This Study

• 23ME-00610 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (13 Sites)

• Stanford Cancer Institute — Palo Alto, California
• Emory University — Atlanta, Georgia
• Karmanos Cancer Institute — Detroit, Michigan
• R.J.Zuckerberg Cancer Center — Lake Success, New York
• Cohen Children's Medical Center — New Hyde Park, New York
• Oregon Health & Science University — Portland, Oregon
• Vanderbilt University — Nashville, Tennessee
• MD Anderson Cancer Center — Houston, Texas
• START Center for Cancer Care — San Antonio, Texas
• Virginia Cancer Specialists — Fairfax, Virginia
• Ottawa Hospital Cancer Centre — Ottawa, Ontario
• Princess Margaret Cancer Centre — Toronto, Ontario
• The Hospital for Sick Children — Toronto, Ontario

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumor

• A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
• A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
• A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
• Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
• A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
• Concurrent Azeliragon With Craniospinal Irradiation — New York, New York

Explore by condition: All Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.